share_log

Have Insiders Sold Janux Therapeutics Shares Recently?

Have Insiders Sold Janux Therapeutics Shares Recently?

近期有內部人士出售了Janux Therapeutics股票嗎?
Simply Wall St ·  10/28 19:13

We wouldn't blame Janux Therapeutics, Inc. (NASDAQ:JANX) shareholders if they were a little worried about the fact that Tighe Reardon, a company insider, recently netted about US$1.8m selling shares at an average price of US$51.81. That sale reduced their total holding by 26% which is hardly insignificant, but far from the worst we've seen.

如果Janux Therapeutics, Inc. (NASDAQ: JANX)的股東們對於公司內部人士Tighe Reardon最近以平均價格51.81美元出售股份套現大約180萬美元感到有些擔憂,我們並不會責怪。 這筆交易導致他們的總持股減少了26%,這並不是無關緊要的,但也遠非我們見過的最糟糕的情況。

The Last 12 Months Of Insider Transactions At Janux Therapeutics

在Janux Therapeutics過去12個月的內部交易中

Notably, that recent sale by Tighe Reardon is the biggest insider sale of Janux Therapeutics shares that we've seen in the last year. So it's clear an insider wanted to take some cash off the table, even slightly below the current price of US$53.41. When an insider sells below the current price, it suggests that they considered that lower price to be fair. That makes us wonder what they think of the (higher) recent valuation. While insider selling is not a positive sign, we can't be sure if it does mean insiders think the shares are fully valued, so it's only a weak sign. It is worth noting that this sale was only 26% of Tighe Reardon's holding.

值得注意的是,Tighe Reardon最近的這筆交易是過去一年中Janux Therapeutics股票最大的內部人士賣出交易。 因此,很明顯某位內部人士想要套現一些現金,甚至略低於當前價格53.41美元。 當一位內部人士以低於當前價格出售股份時,這表明他們認爲較低價格是公平的。 這讓我們想知道他們對(更高的)最近估值的看法。 雖然內部人員出售股份並不是一個積極的跡象,但我們不能確定這是否意味着內部人士認爲股票已經被充分價值化,因此只是一個微弱的跡象。 值得注意的是,這筆交易僅佔Tighe Reardon持股的26%。

Insiders in Janux Therapeutics didn't buy any shares in the last year. The chart below shows insider transactions (by companies and individuals) over the last year. If you want to know exactly who sold, for how much, and when, simply click on the graph below!

Janux Therapeutics的內部人士在過去一年中未購買任何股票。 下圖顯示了過去一年中內部交易(由公司和個人進行)。 如果您想準確了解誰賣出了多少股份,以及何時,只需點擊下方的圖表!

big
NasdaqGM:JANX Insider Trading Volume October 28th 2024
納斯達克GM:JANX 內部交易量2024年10月28日

I will like Janux Therapeutics better if I see some big insider buys. While we wait, check out this free list of undervalued and small cap stocks with considerable, recent, insider buying.

如果我看到一些大額內部買入,我會更喜歡Janux Therapeutics。在等待時,請查看這份免費的低估和小盤股票名單,其中包含最近的內部交易。

Insider Ownership Of Janux Therapeutics

Janux Therapeutics內部所有權

Looking at the total insider shareholdings in a company can help to inform your view of whether they are well aligned with common shareholders. We usually like to see fairly high levels of insider ownership. It's great to see that Janux Therapeutics insiders own 9.7% of the company, worth about US$269m. This kind of significant ownership by insiders does generally increase the chance that the company is run in the interest of all shareholders.

查看公司內部持股總量可以幫助您了解他們是否與普通股東利益保持一致。我們通常希望看到較高比例的內部所有權。很高興看到Janux Therapeutics的內部持股佔公司的9.7%,價值約26900萬美元。內部人士擁有如此大比例的持股,通常會增加公司爲所有股東利益而運行的可能性。

So What Do The Janux Therapeutics Insider Transactions Indicate?

那麼Janux Therapeutics內部交易究竟顯示了什麼?

Insiders haven't bought Janux Therapeutics stock in the last three months, but there was some selling. And even if we look at the last year, we didn't see any purchases. It is good to see high insider ownership, but the insider selling leaves us cautious. So these insider transactions can help us build a thesis about the stock, but it's also worthwhile knowing the risks facing this company. Case in point: We've spotted 4 warning signs for Janux Therapeutics you should be aware of, and 1 of these is a bit concerning.

內部人員在過去三個月內沒有購買Janux Therapeutics的股票,但有一些賣出。即使我們看過去一年的情況,也沒有看到任何購買行爲。看到高比例的內部所有權是好事,但內部賣出讓我們感到謹慎。因此,這些內部交易可以幫助我們建立關於股票的投資理念,但了解這家公司面臨的風險也很重要。舉例:我們發現了Janux Therapeutics有4個警示信號,您應該注意其中一個有點令人擔憂。

But note: Janux Therapeutics may not be the best stock to buy. So take a peek at this free list of interesting companies with high ROE and low debt.

但請注意:Janux Therapeutics也許不是最佳的股票購買選擇。因此,看看這份免費的包含高roe和低債務的有趣公司名單。

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

對於本文而言,內部人是指向相關監管機構報告其交易的個人。我們目前僅考慮公開市場交易和直接利益的私人處置,但不包括衍生交易或間接利益。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對本文有任何反饋?對內容有任何疑慮?請直接與我們聯繫。或者,發送電子郵件至editorial-team@simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論